Management of Hematoma in Patients on Apixaban Therapy

Initial Assessment of Bleeding Severity

The American College of Cardiology defines major bleeding as the presence of at least one of the following criteria: bleeding in a critical site, hemodynamic instability, or a decrease in hemoglobin ≥2 g/dL or need for transfusion ≥2 units of red blood cells 1, 2, 3
Major bleeding is classified based on the presence of critical site bleeding, such as intracranial, intraspinal, intraocular, pericardial, intra-abdominal, retroperitoneal, intra-articular, or intramuscular bleeding 1, 2

The American College of Cardiology recommends immediately stopping apixaban and implementing measures to reverse anticoagulation, including suspending all concomitant antiplatelet agents, providing hemodynamic support and volume resuscitation, applying local therapy/compression when possible, and evaluating and managing comorbidities that contribute to bleeding 1, 2, 3, 4
For major or life-threatening bleeding, andexanet alfa is recommended as a specific reversal agent for apixaban 5, 1, 4

The American College of Cardiology recommends considering surgical or procedural drainage only after controlling coagulopathy and stabilizing the patient 1, 2, 3
The decision to proceed with drainage should be based on criteria such as reversal of anticoagulation, confirmation of hemostasis, hemodynamic stability, and clear surgical indication 5, 1, 2

The American College of Cardiology recommends delaying the restart of anticoagulation if the bleeding occurred in a critical site, the patient is at high risk of rebleeding or death/disability with rebleeding, the source of bleeding has not been definitively treated, or surgical or invasive procedures are planned 6, 4, 7
Anticoagulation should be restarted within 7 days if the patient has a high thrombotic risk (atrial fibrillation with CHA₂DS₂-VASc ≥2, recent venous thromboembolism) and bleeding has been controlled 4, 7

The American College of Cardiology recommends characterizing the hematoma and ruling out complications with ultrasound to determine the size and extent of the organized hematoma, presence of liquefaction or septations, vascular involvement or pseudoaneurysm formation, and baseline documentation for comparison 8
The American College of Cardiology emphasizes that bleeding at critical sites requires more aggressive evaluation and management 8

The American College of Cardiology suggests assessing for signs of compartment syndrome, even in painless presentations, and checking hemoglobin/hematocrit to assess for occult ongoing blood loss 8
Apixaban's effect is prolonged in elderly patients and those with renal impairment, with a half-life extending to 17 hours, which may impact hematoma management 9